Iqvia Holdings (IQV) Current Deferred Revenue (2012 - 2026)
Iqvia Holdings' (IQV) quarterly Current Deferred Revenue came in at $2.3 billion in Q2 2026, up 7.44% year-over-year from $2.1 billion in Q2 2025, and up 0.88% quarter-over-quarter from $2.3 billion in Q1 2026.
Analysis
Iqvia Holdings (IQV) Current Deferred Revenue (2012 - 2026) Analysis & Trends
Iqvia Holdings has disclosed Current Deferred Revenue across 15 years of filings, most recently posting $2.3 billion for Q2 2026.
- In Q2 2026, Current Deferred Revenue rose 7.44% year-over-year to $2.3 billion; the TTM figure through Jun 2026 stood at $2.3 billion (up 7.44% YoY), while the FY2025 annual figure was $2.1 billion, up 19.06% from the prior year.
- Current Deferred Revenue came in at $2.3 billion for Q2 2026 at Iqvia Holdings, up from $2.3 billion in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $2.3 billion in Q2 2026 to a low of $1.8 billion in Q4 2024.
- Average Current Deferred Revenue over 5 years is $1.9 billion, with a median of $1.8 billion recorded in 2022.
- Year-over-year, Current Deferred Revenue climbed 24.0% in 2022 and fell 5.19% in 2023.
- Over 5 years, Current Deferred Revenue stood at $1.8 billion in 2022, then rose by 0.11% to $1.8 billion in 2023, then dropped by 1.11% to $1.8 billion in 2024, then grew by 19.06% to $2.1 billion in 2025, then increased by 7.7% to $2.3 billion in 2026.
- Per Business Quant data, the three most recent Current Deferred Revenue figures were $2.3 billion in Q2 2026, $2.3 billion in Q1 2026, and $2.1 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.28 Bn |
| Mar 31, 2026 | 2.26 Bn |
| Dec 31, 2025 | 2.12 Bn |
| Sep 30, 2025 | 2.16 Bn |
| Jun 30, 2025 | 2.12 Bn |
| Mar 31, 2025 | 1.94 Bn |
| Dec 31, 2024 | 1.78 Bn |
| Sep 30, 2024 | 1.82 Bn |
| Jun 30, 2024 | 1.81 Bn |
| Mar 31, 2024 | 1.91 Bn |
| Dec 31, 2023 | 1.80 Bn |
| Sep 30, 2023 | 1.84 Bn |
| Jun 30, 2023 | 1.84 Bn |
| Mar 31, 2023 | 1.83 Bn |
| Dec 31, 2022 | 1.80 Bn |
| Sep 30, 2022 | 1.84 Bn |
| Jun 30, 2022 | 1.81 Bn |
| Mar 31, 2022 | 1.93 Bn |
| Dec 31, 2021 | 1.83 Bn |
| Sep 30, 2021 | 1.83 Bn |